A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy

Running, not enrolling · Not applicable

Conditions studied: Acute Myeloid Leukemia, Myelodysplastic Syndromes

In brief

This research study is evaluating the impact a collaborative palliative care and oncology team will have on end-of-life outcomes, quality of end-of-life care, and the quality of life, symptoms, and mood of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy

Key facts

Study ID

NCT03310918

Run by

Massachusetts General Hospital

People needed

320

Starts

2017-10-31

Expected to finish

2026-12-31

Last updated by the study team

2026-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with AML receiving non-intensive therapy including hypomethylating agents, single-agent chemotherapy, targeted therapy agents, or single or combination non-intensive agents offered on a clinical trial, including the following populations:
• Newly diagnosed AML
• Relapsed AML
• Primary refractory AML
• The ability to provide informed consent
• The ability to comprehend English or complete questionnaires with minimal assistance of an interpreter

You may not qualify if…

• Patients not receiving care at MGH
• Patients receiving intensive chemotherapy (requiring 4-6 week hospitalization)
• Patients receiving supportive care alone
• Major psychiatric illness or co-morbid conditions prohibiting compliance with study procedures
• Patients already receiving palliative care

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.